Role of CDK4/6 Inhibitors in Targeting Rb Proficient Small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2024 Feb 26

PMID 38404986

Authors

Virginia Corbett

Triparna Sen

Aman Chauhan

Affiliations

Soon will be listed here.

References

Schaffer B, Park K, Yiu G, Conklin J, Lin C, Burkhart D . Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010; 70(10):3877-83. PMC: 2873158. DOI: 10.1158/0008-5472.CAN-09-4228. View

Moriya R, Hokari S, Shibata S, Koizumi T, Tetsuka T, Ito K . Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report. Intern Med. 2017; 56(15):2013-2017. PMC: 5577079. DOI: 10.2169/internalmedicine.56.7452. View

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

Marcoux N, Gettinger S, OKane G, Arbour K, Neal J, Husain H . EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2018; 37(4):278-285. PMC: 7001776. DOI: 10.1200/JCO.18.01585. View

Inoue Y, Nikolic A, Farnsworth D, Shi R, Johnson F, Liu A . Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. Elife. 2021; 10. PMC: 8337080. DOI: 10.7554/eLife.66524. View

Rudin C, Poirier J, Byers L, Dive C, Dowlati A, George J . Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019; 19(5):289-297. PMC: 6538259. DOI: 10.1038/s41568-019-0133-9. View

Corbett V, Hallenbeck P, Rychahou P, Chauhan A . Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Front Mol Biosci. 2022; 9:930207. PMC: 9458967. DOI: 10.3389/fmolb.2022.930207. View

Meuwissen R, Linn S, Linnoila R, Zevenhoven J, Mooi W, Berns A . Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003; 4(3):181-9. DOI: 10.1016/s1535-6108(03)00220-4. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

10.

George J, Lim J, Jang S, Cun Y, Ozretic L, Kong G . Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524(7563):47-53. PMC: 4861069. DOI: 10.1038/nature14664. View

11.

Ireland A, Micinski A, Kastner D, Guo B, Wait S, Spainhower K . MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell. 2020; 38(1):60-78.e12. PMC: 7393942. DOI: 10.1016/j.ccell.2020.05.001. View

12.

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

13.

Niederst M, Sequist L, Poirier J, Mermel C, Lockerman E, Garcia A . RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015; 6:6377. PMC: 4357281. DOI: 10.1038/ncomms7377. View

14.

Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A . Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clin Proc. 2017; 92(8):1304-1311. DOI: 10.1016/j.mayocp.2017.03.022. View

15.

Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson T . Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel). 2021; 13(8). PMC: 8067543. DOI: 10.3390/cancers13081753. View

16.

Duplaquet L, Li Y, Booker M, Xie Y, Olsen S, Patel R . KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. Nat Cell Biol. 2023; 25(9):1346-1358. PMC: 10546329. DOI: 10.1038/s41556-023-01210-z. View

17.

Zhao J, Shao J, Zhao R, Li R, Yu K, Zhu L . Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma. Thorac Cancer. 2017; 9(1):129-135. PMC: 5754316. DOI: 10.1111/1759-7714.12549. View

18.

Rudin C, Brambilla E, Faivre-Finn C, Sage J . Small-cell lung cancer. Nat Rev Dis Primers. 2021; 7(1):3. PMC: 8177722. DOI: 10.1038/s41572-020-00235-0. View

19.

Baine M, Hsieh M, Lai W, Egger J, Jungbluth A, Daneshbod Y . SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020; 15(12):1823-1835. PMC: 8362797. DOI: 10.1016/j.jtho.2020.09.009. View

20.

Wildey G, Shay A, McColl K, Yoon S, Shatat M, Perwez A . Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer. Mol Cancer Ther. 2022; 22(2):264-273. PMC: 9898162. DOI: 10.1158/1535-7163.MCT-22-0365. View